Clinton/Reid Bill Would Boost Cancer Tracking at CDC

Publication
Article
OncologyONCOLOGY Vol 16 No 8
Volume 16
Issue 8

Now that President Bush has appointed Julie Gerberding to head the Centers for Disease Control and Prevention (CDC), groups like the Trust for America’s Health are urging her to make cancer tracking a priority.

Now that President Bush has appointed Julie Gerberding to head the Centersfor Disease Control and Prevention (CDC), groups like the Trust for America’sHealth are urging her to make cancer tracking a priority. 

A new bill—the Nationwide Health Tracking Act—introduced by Sen. HillaryClinton (D-NY) and Sen. Harry Reid (D-Nev) would authorize $227.5 million a yearfor expansion of a pilot CDC chronic disease tracking program. The Clinton/Reidbill, which has a counterpart in the House, grew out of hearings held in Fallon,Nev, and Long Island, NY, that focused on possible environmental links to cancerin those communities. 

Congress gave the CDC $17.5 million in fiscal 2002 to help get itsenvironmental health-tracking program off the ground. But at that funding level,the program’s reach is limited. Shelley Hearne, executive director of theTrust, points out that Congress just gave the CDC an extra $1 billion forbioterrorism. "But this funding and the CDC’s guidelines on how to spendit do not help the nation prepare for the number 1 killer of Americans today—chronicdiseases like cancer, asthma, and Parkinson’s disease," she states.

Recent Videos
Patients with AML will experience different toxicities based on the treatment they receive, whether it is intensive chemotherapy or targeted therapy.
A younger patient with AML who is more fit may be eligible for different treatments than an older patient with chronic medical conditions.
Breast cancer care providers make it a goal to manage the adverse effects that patients with breast cancer experience to minimize the burden of treatment.
Social workers and case managers may have access to institutional- or hospital-level grants that can reduce financial toxicity for patients undergoing cancer therapy.
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Related Content